Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Ask the Analyst
Partnered Content
PDF Library
RSS Feeds
Subscribe
FAQs
Advertising
Report Store
UsernamePublicRestriction
Tags:
Consumer OTC Drugs

J&J/Merck Bolsters Heartburn Lineup With Maximum Strength Pepcid AC

This article was originally published in The Tan Sheet

  • News
  • The Tan Sheet

Executive Summary

New heartburn prevention/relief product Maximum Strength Pepcid AC will hit shelves Oct. 17, following FDA approval of the new dosage Sept. 24, according to Johnson & Johnson/Merck

You may also be interested in...



Pfizer Looks To Give J&J/Merck Heartburn With Zantac 150 Switch

Pfizer Consumer Healthcare's Rx-to-OTC switch of Zantac 150 appears to be a belated attempt to counter Johnson & Johnson/Merck's approval of Maximum Strength Pepcid AC last year

Pfizer Looks To Give J&J/Merck Heartburn With Zantac 150 Switch

Pfizer Consumer Healthcare's Rx-to-OTC switch of Zantac 150 appears to be a belated attempt to counter Johnson & Johnson/Merck's approval of Maximum Strength Pepcid AC last year

Pfizer Looks To Give J&J/Merck Heartburn With Zantac 150 Switch

Pfizer Consumer Healthcare's Rx-to-OTC switch of Zantac 150 appears to be a belated attempt to counter Johnson & Johnson/Merck's approval of Maximum Strength Pepcid AC last year

Table

View full table

Related Content

Pink Sheet
Pink Sheet
Pink Sheet
Pink Sheet
Pink Sheet
Pink Sheet

Topics

Tags:
Consumer OTC Drugs
UsernamePublicRestriction

Register

LL1135866

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By